Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease
- PMID: 21117058
- PMCID: PMC3233349
- DOI: 10.1002/ajh.21883
Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease
Abstract
The attitudes of patients with sickle cell disease (SCD) toward the use of hydroxyurea (HU) therapy may contribute to the underutilization of HU in the United States, yet our understanding of these attitudes is limited. We examined the attitudes and beliefs of 94 adult SCD patients, comparing those who never used HU (n 5 37), formerly used HU (n 5 23), and were currently using HU (n 5 34). Seventy percent of current HU users reported some level of improvement from the drug ("average" or "very much") and 80% reported little or no trouble from side effects. Fifty-seven percent of former users reported taking HU for less than 6 months, with "doctor"s recommendation," or "not liking the way it made me feel" given as the most commonly reported reasons for stopping HU. Fifty percent of the never users reported receiving no information about HU from any source, and 85% of the never users thought that they would receive no improvement if they were to take HU. A deeper understanding of patient perspectives toward HU utilization is required as part of multipronged efforts to combat its underutilization in the treatment of SCD.
Similar articles
-
Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.Ann Afr Med. 2021 Apr-Jun;20(2):127-131. doi: 10.4103/aam.aam_36_20. Ann Afr Med. 2021. PMID: 34213480 Free PMC article.
-
Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study.BMC Health Serv Res. 2024 May 27;24(1):666. doi: 10.1186/s12913-024-11125-6. BMC Health Serv Res. 2024. PMID: 38802815 Free PMC article.
-
Hydroxyurea for the treatment of sickle cell disease.Evid Rep Technol Assess (Full Rep). 2008 Mar;(165):1-95. Evid Rep Technol Assess (Full Rep). 2008. PMID: 18457478 Free PMC article. Review.
-
Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.Hemoglobin. 2019 May;43(3):188-192. doi: 10.1080/03630269.2019.1649278. Epub 2019 Aug 29. Hemoglobin. 2019. PMID: 31462098
-
Hydroxyurea in children: present and future.Semin Hematol. 1997 Jul;34(3 Suppl 3):22-9. Semin Hematol. 1997. PMID: 9317198 Review.
Cited by
-
Barriers and Facilitators of Use of Hydroxyurea among Children with Sickle Cell Disease: Experiences of Stakeholders in Tanzania.Hemato. 2021 Dec;2(4):713-726. doi: 10.3390/hemato2040048. Epub 2021 Nov 28. Hemato. 2021. PMID: 39211482 Free PMC article.
-
Understanding multi-level barriers to medication adherence among adults living with sickle cell disease.Medicine (Baltimore). 2023 Oct 13;102(41):e35400. doi: 10.1097/MD.0000000000035400. Medicine (Baltimore). 2023. PMID: 37832127 Free PMC article.
-
Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators.Br J Haematol. 2023 Dec;203(5):712-721. doi: 10.1111/bjh.19099. Epub 2023 Sep 10. Br J Haematol. 2023. PMID: 37691131 Review.
-
Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease.Curr Ther Res Clin Exp. 2023 Feb 23;98:100696. doi: 10.1016/j.curtheres.2023.100696. eCollection 2023. Curr Ther Res Clin Exp. 2023. PMID: 36950457 Free PMC article.
-
Development and Validation of the Patient/Caregiver Reported Hydroxyurea Evaluation of Adherence for Life (HEAL) Scale.Patient Prefer Adherence. 2022 Dec 10;16:3229-3239. doi: 10.2147/PPA.S387227. eCollection 2022. Patient Prefer Adherence. 2022. PMID: 36531301 Free PMC article.
References
-
- Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332:1317–1322. - PubMed
-
- Moore RD, Charache S, Terrin ML, et al. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Am J Hematol. 2000;64:26–31. - PubMed
-
- Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645–1651. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K08 HS013903/HS/AHRQ HHS/United States
- 5KL2RR025006-03/RR/NCRR NIH HHS/United States
- R01 HL088511-01A1/HL/NHLBI NIH HHS/United States
- R01 HL088511-03/HL/NHLBI NIH HHS/United States
- 5K08HS013903-04/HS/AHRQ HHS/United States
- F31 HL082037/HL/NHLBI NIH HHS/United States
- 5K23HL083089-02/HL/NHLBI NIH HHS/United States
- K23 HL083089/HL/NHLBI NIH HHS/United States
- R01 HL088511/HL/NHLBI NIH HHS/United States
- KL2 RR025006/RR/NCRR NIH HHS/United States
- R01 HL088511-02/HL/NHLBI NIH HHS/United States
- 5F31HL082037-02/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical